What are the prospects for a pharmacological approach to incontinence caused by pelvic organ prolapse?
In terms of the pharmacological approach to incontinence we have to distinguish between overactive bladder and stress incontinence. For urge incontinence there are recent data published by my group which show that antimuscarinics are not so effective in women with anterior vaginal wall prolapse with concomitant overactive bladder. So in other terms, it is always better to restore anatomy before giving an antimuscarinic drug. In terms of stress incontinence, there is evidence that the SSRI category, duloxetine in particular, has good efficacy in improving stress incontinence even in women with prolapse, when you repair the prolapse at the same time. The only problem is that this class of drug may have side effects which may limit their use on a long-term basis. What is the state-of-the-art of biomaterials in pelvic organ prolapse repair? What results and complications have been found with the use of meshes in the surgical correction of prolapse? In terms of the use of grafts we have to
